Comparison of the Structure and Activity of Glycosylated and Aglycosylated Human Carboxylesterase 1

Human Carboxylesterase 1 (hCES1) is the key liver microsomal enzyme responsible for detoxification and metabolism of a variety of clinical drugs. To analyse the role of the single N-linked glycan on the structure and activity of the enzyme, authentically glycosylated and aglycosylated hCES1, generated by mutating asparagine 79 to glutamine, were produced in human embryonic kidney cells. Purified enzymes were shown to be predominantly trimeric in solution by analytical ultracentrifugation. The purified aglycosylated enzyme was found to be more active than glycosylated hCES1 and analysis of enzyme kinetics revealed that both enzymes exhibit positive cooperativity. Crystal structures of hCES1 a catalytically inactive mutant (S221A) and the aglycosylated enzyme were determined in the absence of any ligand or substrate to high resolutions (1.86 Å, 1.48 Å and 2.01 Å, respectively). Superposition of all three structures showed only minor conformational differences with a root mean square deviations of around 0.5 Å over all Cα positions. Comparison of the active sites of these un-liganded enzymes with the structures of hCES1-ligand complexes showed that side-chains of the catalytic triad were pre-disposed for substrate binding. Overall the results indicate that preventing N-glycosylation of hCES1 does not significantly affect the structure or activity of the enzyme.

[1]  M. Imwong,et al.  Efficient in vitro refolding and functional characterization of recombinant human liver carboxylesterase (CES1) expressed in E. coli , 2015, Protein expression and purification.

[2]  P. Andrew Karplus,et al.  Linking Crystallographic Model and Data Quality , 2012, Science.

[3]  J. Sussman,et al.  Structure of recombinant human carboxylesterase 1 isolated from whole cabbage looper larvae. , 2012, Acta crystallographica. Section F, Structural biology and crystallization communications.

[4]  A. H. Drummond,et al.  Drug Targeting to Monocytes and Macrophages Using Esterase-Sensitive Chemical Motifs , 2011, Journal of Pharmacology and Experimental Therapeutics.

[5]  Elizabeth I. Parkinson,et al.  Requirements for mammalian carboxylesterase inhibition by substituted ethane-1,2-diones. , 2011, Bioorganic & medicinal chemistry.

[6]  L. Maltais,et al.  Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins , 2010, Mammalian Genome.

[7]  J. Cashman,et al.  Human Carboxylesterase 1 Stereoselectively Binds the Nerve Agent Cyclosarin and Spontaneously Hydrolyzes the Nerve Agent Sarin , 2010, Molecular Pharmacology.

[8]  Fabrice Gorrec,et al.  The MORPHEUS protein crystallization screen , 2009, Journal of applied crystallography.

[9]  T. Saitoh,et al.  Allosteric kinetics of human carboxylesterase 1: species differences and interindividual variability. , 2008, Journal of pharmaceutical sciences.

[10]  Masakiyo Hosokawa,et al.  Structure and Catalytic Properties of Carboxylesterase Isozymes Involved in Metabolic Activation of Prodrugs , 2008, Molecules.

[11]  M. Redinbo,et al.  Crystal structures of human carboxylesterase 1 in covalent complexes with the chemical warfare agents soman and tabun. , 2007, Biochemistry.

[12]  Bruce D. Hammock,et al.  Analysis of Mammalian Carboxylesterase Inhibition by Trifluoromethylketone-Containing Compounds , 2007, Molecular Pharmacology.

[13]  David J. Harvey,et al.  Glycoprotein Structural Genomics: Solving the Glycosylation Problem , 2007, Structure.

[14]  David Alderton,et al.  A versatile ligation-independent cloning method suitable for high-throughput expression screening applications , 2007, Nucleic acids research.

[15]  Peter Kuhn,et al.  Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1. , 2006, Journal of molecular biology.

[16]  Weixian Lu,et al.  A time- and cost-efficient system for high-level protein production in mammalian cells. , 2006, Acta crystallographica. Section D, Biological crystallography.

[17]  P. Potter,et al.  Carboxylesterases--detoxifying enzymes and targets for drug therapy. , 2006, Current medicinal chemistry.

[18]  Janet Newman,et al.  Towards rationalization of crystallization screening for small- to medium-sized academic laboratories: the PACT/JCSG+ strategy. , 2005, Acta crystallographica. Section D, Biological crystallography.

[19]  Sompop Bencharit,et al.  Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. , 2005, Journal of molecular biology.

[20]  Lester G. Carter,et al.  A procedure for setting up high‐throughput nanolitre crystallization experiments. Crystallization workflow for initial screening, automated storage, imaging and optimization , 2005, Acta crystallographica. Section D, Biological crystallography.

[21]  Matthew R. Redinbo,et al.  Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme , 2003, Nature Structural Biology.

[22]  P. Kuhn,et al.  Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. , 2003, Chemistry & biology.

[23]  Philip J. Reeves,et al.  Structure and function in rhodopsin: A tetracycline-inducible system in stable mammalian cell lines for high-level expression of opsin mutants , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Vance,et al.  Structure-function analysis of human triacylglycerol hydrolase by site-directed mutagenesis: identification of the catalytic triad and a glycosylation site. , 2002, Biochemistry.

[25]  M. Wierdl,et al.  Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. , 2001, Molecular pharmacology.

[26]  C. Morton,et al.  Comparison of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Spodoptera frugiperda, and COS7 cells for recombinant gene expression , 2000, Molecular biotechnology.

[27]  C. Morton,et al.  Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). , 1998, Cancer research.

[28]  T. Uematsu,et al.  Purification and characterization of guinea-pig liver microsomal deacetylase involved in the deacetylation of the O-glucoside of N-hydroxyacetanilide. , 1997, The Biochemical journal.

[29]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[30]  T. Satoh,et al.  Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. , 1994, Biological & pharmaceutical bulletin.

[31]  D. Kroetz,et al.  Glycosylation-dependent activity of baculovirus-expressed human liver carboxylesterases: cDNA cloning and characterization of two highly similar enzyme forms. , 1993, Biochemistry.

[32]  Joel L. Sussman,et al.  The α/β hydrolase fold , 1992 .

[33]  S. Ho,et al.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction. , 1989, Gene.

[34]  D I Stuart,et al.  Crystal structure of cat muscle pyruvate kinase at a resolution of 2.6 A. , 1979, Journal of molecular biology.

[35]  G. J. Tompkins,et al.  The establishment of two cell lines from the insectspodoptera frugiperda (lepidoptera; noctuidae) , 1977, In Vitro.

[36]  J. Changeux,et al.  ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. , 1965, Journal of molecular biology.

[37]  R. Owens,et al.  Transient expression in HEK 293 cells: an alternative to E. coli for the production of secreted and intracellular mammalian proteins. , 2015, Methods in molecular biology.

[38]  P. Potter,et al.  Inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by chlorpyrifos oxon, paraoxon and methyl paraoxon. , 2012, Toxicology and applied pharmacology.

[39]  P. Potter,et al.  Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. , 2011, Biochemical pharmacology.

[40]  R. Owens,et al.  The production of glycoproteins by transient expression in Mammalian cells. , 2009, Methods in molecular biology.

[41]  Bruce D Hammock,et al.  Characterization of pyrethroid hydrolysis by the human liver carboxylesterases hCE-1 and hCE-2. , 2006, Archives of biochemistry and biophysics.

[42]  Biological Crystallography , 2004 .

[43]  M. Redinbo,et al.  Structural insights into CPT-11 activation by mammalian carboxylesterases , 2002, Nature Structural Biology.

[44]  M Hosokawa,et al.  The mammalian carboxylesterases: from molecules to functions. , 1998, Annual review of pharmacology and toxicology.

[45]  S J Remington,et al.  The alpha/beta hydrolase fold. , 1992, Protein engineering.

[46]  D. Koshland,et al.  Comparison of experimental binding data and theoretical models in proteins containing subunits. , 1966, Biochemistry.

[47]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Translation Functions Biological Crystallography Likelihood-enhanced Fast Translation Functions , 2022 .